|
Synonyms: BYM-338 | BYM338
Compound class:
Antibody
Comment: Bimagrumab is an investigational monoclonal antibody designed to treat the pathological muscle loss and weakness caused by the inflammatory muscle depleting disease, sporadic inclusion body myositis (sIBM).
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Amato AA, Sivakumar K, Goyal N, David WS, Salajegheh M, Praestgaard J, Lach-Trifilieff E, Trendelenburg AU, Laurent D, Glass DJ et al.. (2014)
Treatment of sporadic inclusion body myositis with bimagrumab. Neurology, 83 (24): 2239-46. [PMID:25381300] |
|
2. Berger C, Herrmann T, Lu C, Sheppard K-A, Trifilieff E, Urlinger S. (2013)
Compositions and methods for increasing muscle growth. Patent number: US8388968. Assignee: Novartis Ag. Priority date: 27/04/2009. Publication date: 05/03/2013. |
|
3. Bogdanovich S, McNally EM, Khurana TS. (2008)
Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve, 37 (3): 308-16. [PMID:18041051] |
|
4. Han HQ, Zhou X, Mitch WE, Goldberg AL. (2013)
Myostatin/activin pathway antagonism: molecular basis and therapeutic potential. Int J Biochem Cell Biol, 45 (10): 2333-47. [PMID:23721881] |
